CAR-T Cell Therapy for Hepatitis B with Reduced Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis B virus (HBV) infection are limited, with reverse transcriptase inhibitors only suppressing HBV DNA levels and recombinant interferon alpha derivatives causing significant side effects and inducing HBsAg seroconversion in only a small percentage of patients, while chronic HBV patients have a deficiency in HBV-specific T cells in numbers and functionality.
Innovation Solution
The use of immunotherapy involving immune cells, such as T-lymphocytes or natural killer cells engineered to express chimeric antigen receptors (CARs) that target HBV antigens, with modifications to reduce cytotoxicity and enhance specificity and persistence, such as genetic knockouts or siRNA treatment, to effectively target and eliminate HBV-infected cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If reverse transcriptase inhibitors are used to treat HBV infection, then HBV DNA levels are suppressed, but the treatment only provides suppression without functional cure and has limited efficacy
Solution Approach 1:
The patent introduces engineered T cells as an intermediary therapeutic agent that bridges the gap between antiviral suppression and immune-mediated clearance. These CAR-T cells specifically recognize HBV antigens and eliminate infected hepatocytes, providing a functional cure mechanism that RT inhibitors alone cannot achieve.
Solution Approach 2:
The patent modifies T cell parameters through genetic engineering to enhance their anti-HBV functionality. This includes introducing chimeric antigen receptors with specific binding affinities for HBV antigens, adjusting cytokine profiles, and optimizing persistence characteristics to improve treatment efficacy beyond conventional therapy.
2Reliability
If recombinant interferon alpha derivatives are used to treat HBV infection, then HBsAg seroconversion is induced in some patients, but significant side effects occur and only a small percentage of patients achieve seroconversion
Solution Approach 1:
The patent extracts the desired immunomodulatory and antiviral effects of interferon therapy while eliminating its harmful side effects by using genetically engineered T cells. These CAR-T cells provide targeted anti-HBV activity through antigen-specific recognition and cytotoxic elimination of infected cells without causing the systemic side effects associated with interferon alpha derivatives.
Solution Approach 2:
The engineered T cells function as a disposable therapeutic agent that can be administered in controlled doses. Unlike interferon that requires continuous administration and causes cumulative toxicity, the CAR-T cells provide sustained therapeutic effect through persistent presence and self-renewal capacity, reducing the need for long-term treatment and associated side effects.
3Reliability
If immune cells are engineered to express CARs that target HBV antigens, then therapeutic efficacy is improved, but cytotoxicity may cause liver toxicity
Solution Approach 1:
The patent applies local quality control by engineering CAR-T cells with restricted cytotoxic function. The CAR molecules are designed to recognize specific HBV antigens with high specificity, limiting the cytotoxic activity to only HBV-infected hepatocytes expressing these antigens. This spatial and functional specificity prevents off-target damage to healthy liver tissue while maintaining effective clearance of infected cells.
Solution Approach 2:
The patent employs partial action by modulating the cytotoxic potency of the engineered T cells. The CAR design and T cell engineering parameters are optimized to achieve sufficient viral clearance without excessive cytotoxicity that would cause liver damage. This includes tuning the affinity of the antigen-binding component and adjusting the strength of the signaling domains to achieve therapeutic efficacy below the threshold of hepatotoxicity.
4Duration of action of moving object
If chronic HBV patients receive conventional therapy, then treatment is prolonged, but HBV-specific T cell deficiency in numbers and functionality persists
Solution Approach 1:
The patent implements preliminary action by pre-engineering T cells with enhanced anti-HBV capabilities before administration. The CAR-T cells are genetically modified in advance to express high-affinity antigen receptors, optimized cytokine profiles, and enhanced persistence characteristics. This pre-conditioning allows the cells to immediately exert therapeutic effect upon infusion, overcoming the T cell deficiency that has persisted throughout chronic infection without requiring prolonged treatment to rebuild immune function.
Data Source
AI summary
Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised.